| Advanced group (n = 40) | Extrinsic group (n = 9) | Intrinsic group (n = 3) | P-value |
---|---|---|---|---|
Number of oocyte retrieval cycles | 2 (1–9) | 2 (1–4) | 1 | 0.210 |
Type of controlled ovarian stimulation, n (%) | Â | Â | Â | 0.068 |
Short | 49/111 (44.1) | 4/21 (19) | 0/3 | Â |
Long | 26/111 (23.4) | 11/21 (52.4) | 1/3 (33.3) | Â |
Ultra-long | 16/111 (14.4) | 2/21 (9.5) | 1/3 (33.3) | Â |
GnRH antagonist | 15/111 (13.5) | 3/21 (14.3) | 1/3 (33.3) | Â |
Others | 5/111 (4.5) | 1/21 (4.8) | 0/3 | Â |
Total dose of gonadotropin used (IU) | 2400 (225–6750) | 2250 (600–2250) | 1425 (1025–2625) | 0.162 |
Number of oocytes retrieved | 2 (0–15) | 4 (1–11) | 8 (8–14) | 0.008 |
Fertilisation method, n (%) | Â | Â | Â | 0.616 |
ICSI | 35/106 (33.0) | 6/21 (28.6) | 2/3 (66.7) | Â |
IVF | 67/106 (63.2) | 14/21 (66.7) | 1/3 (33.3) | Â |
Mixed | 4/106 (3.8) | 1/21 (4.7) | 0/3 | Â |
Number of ET cycles | 2 (1–8) | 3 (2–5) | 3 (2–4) | 0.129 |
Number of ET/cycles | 1 (1–2) | 1 (1–2) | 1 (1–2) | 0.802 |
ET type, n (%) | Â | Â | Â | 0.083 |
Fresh | 49/100 (49) | 11/27 (40.7) | 1/9 (11.1) | Â |
Frozen-thawed | 51/100 (51) | 16/27 (59.3) | 8/9 (88.9) | Â |
Embryo quality, (%) | Â | Â | Â | 0.034 |
Good | 77/100 (77) | 16/27 (59.3) | 9/9 (100) | Â |
Long-term pituitary down-regulation before ET, n (%) | 20/100 (20) | 1/27 (3.7) | 0/9 | 0.048 |